Most Favored Patient Act of 2026

The Most Favored Patient Act of 2026 (HR7837) was introduced in the House on March 5, 2026, by Rep. Meuser (R-PA). The bill aims to amend the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing, starting January 1, 2029. This model would compel pharmaceutical manufacturers to offer their lowest global drug prices for Medicare-covered drugs. The bill has been referred to the Committees on Energy and Commerce and Ways and Means, indicating it is in the initial stages of the legislative process. This bill does not authorize or appropriate a specific funding amount. Instead, it mandates a pricing model that would directly impact the revenue streams of pharmaceutical companies by setting a ceiling on drug prices for Medicare. The mechanism is regulatory, forcing price reductions rather than allocating funds. The bill text specifies that manufacturers must provide access to the most-favored-nation price for covered drugs to eligible individuals and providers. Structural losers under this proposed legislation would be major pharmaceutical companies that currently charge higher prices for their drugs in the U.S. compared to other countries. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck & Co. ($MRK), Eli Lilly and Company ($LLY), AbbVie Inc. ($ABBV), Amgen Inc. ($AMGN), GSK plc ($GSK), AstraZeneca PLC ($AZN), and Sanofi ($SNY) would face direct revenue pressure if this bill were to become law. The bill's intent is to reduce drug costs for Medicare, which translates to reduced profitability for drug manufacturers. Looking at recent market data, over the past 30 days, several major pharmaceutical companies have seen mixed performance: Pfizer ($PFE) is up +4.58%, Johnson & Johnson ($JNJ) is up +0.56%, Merck & Co. ($MRK) is up +4.12%, Eli Lilly and Company ($LLY) is down -5.72%, AbbVie Inc. ($ABBV) is down -11.04%, Amgen Inc. ($AMGN) is down -6.81%, GSK plc ($GSK) is up +1.99%, AstraZeneca PLC ($AZN) is up +2.69%, and Sanofi ($SNY) is up +5.78%. The introduction of this bill has not yet led to a uniform negative market reaction across the sector, likely due to its early legislative stage. The bill's effective date of January 1, 2029, also provides a significant lead time for companies to adjust or for the legislative process to evolve. The next steps for this bill involve committee consideration and potential markups, followed by votes in the House and then the Senate, before it could reach the President's desk.